Open AccessSystemic treatment for hepatocellular carcinoma
Author(s) -
Tokarčík Ján,
Slížová Dáša,
Igor Andrašina,
Vaculová Jana
Publication year - 2020
Publication title -
klinická onkologie
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.204
H-Index - 13
eISSN - 1802-5307
pISSN - 0862-495X
DOI - 10.14735/amko2020356
Subject(s) - sorafenib , medicine , regorafenib , hepatocellular carcinoma , ramucirumab , liver transplantation , oncology , disease , incidence (geometry) , cancer , cabozantinib , transplantation , colorectal cancer , physics , optics
Hepatocellular carcinoma (HCC) is one of the most common types of cancer with increasing incidence. It accounts for approximately 90% of primary liver cancers and it is a significant global health problem. Globally, it represents the 5th most common disease and it is considered to be the third most common cause of cancer related deaths. The occurrence of HCC is related to environmental factors, eating habits and lifestyle. It is more common in men than in women. The highest incidence of HCC is in Southeast Asia, China, West and Central Africa, and among immigrants from high-risk areas in the United States. In North America, Europe and Japan, hepatitis C virus infection is its major risk factor along with alcohol consumption. Modern therapeutic methods improved the results of the treatment in patients with HCC. In early stages of HCC, curative treatment, surgical resection, liver transplantation, and radiofrequency ablation are possible. In advanced disease, local chemotherapy and systemic targeted therapy have prolonged survival.